Given the prevalence of HER2 positivity in other solid tumors, such as gastric cancer and bladder cancer [51], our finding may expand the potential utility of Melatonin in HER2-targeted therapies beyond breast cancer. The gene discussed is ERBB2; the disease is gastric cancer.